Extended Lymph-Node Dissection for Gastric Cancer
- 25 March 1999
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (12), 908-914
- https://doi.org/10.1056/nejm199903253401202
Abstract
Curative resection is the treatment of choice for gastric cancer, but it is unclear whether this operation should include an extended (D2) lymph-node dissection, as recommended by the Japanese medical community, or a limited (D1) dissection. We conducted a randomized trial in 80 Dutch hospitals in which we compared D1 with D2 lymph-node dissection for gastric cancer in terms of morbidity, postoperative mortality, long-term survival, and cumulative risk of relapse after surgery.This publication has 21 references indexed in Scilit:
- Risk factors for surgical treatment in the Dutch gastric cancer trialBritish Journal of Surgery, 1997
- Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancerBritish Journal of Surgery, 1996
- Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trialThe Lancet, 1996
- Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patientsThe Lancet, 1995
- Prognostic factors in gastric carcinoma. Results of the German gastric carcinoma study 1992Cancer, 1993
- Extensive versus limited lymph node dissection for gastric cancer: A comparative study of 320 patientsBritish Journal of Surgery, 1993
- Improving survival in gastric cancer: Review of 5-year survival rates in English language publications from 1970British Journal of Surgery, 1992
- Morbidity of Radical Lymphadenectomy in the Curative Resection of Gastric CarcinomaArchives of Surgery, 1991
- The general rules for the gastric cancer study in surgery and pathologySurgery Today, 1981
- Early results of extended total gastrectomy for cancerCancer, 1956